Clinical trial · Observational
Precision Medicine for Every Child With Cancer
NCT05504772CI-TRIAL-00078875ZERO2recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To improve outcomes for childhood cancer patients through the implementation of precision medicine.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Childhood Brain Tumor | Childhood Brain Neoplasm | ALIAS | 0.90 |
| Childhood Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
| Childhood Leukemia | Childhood Leukemia | ONTOLOGY_EXACT | 0.98 |
| Childhood Solid Tumor | Childhood Solid Neoplasm | ALIAS | 0.90 |
| Refractory Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Relapsed Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DNA Methylation | Genetic | — | UNRESOLVED |
| High Throughput Sequencing (in vitro) | Genetic | — | UNRESOLVED |
| Liquid Biopsy | Other | — | UNRESOLVED |
| Patient Derived Xenograft (PDX)(in vivo) | Genetic | — | UNRESOLVED |
| RNA seq | Genetic | — | UNRESOLVED |
| Targeted Panel Sequencing | Genetic | — | UNRESOLVED |
| Whole Genome Sequencing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (13)
- label
- High-risk cancers
- description
- One of the following two criteria must be met: 1. Confirmed or suspected high-risk malignancy defined as expected overall survival \< 30% based on current literature for the specific cancer 2. Cancers for which standard therapy would result in unacceptable and severe morbidity (e.g., infantile fibrosarcoma where definitive surgery would require amputation of limb) Note: This does not include HR neuroblastoma at diagnosis as this group of patients have an overall survival ≥30% and belongs to Cohort 4A.
- interventionNames
- Genetic: Whole Genome Sequencing
- Genetic: RNA seq
- Genetic: DNA Methylation
- Genetic: Targeted Panel Sequencing
- Genetic: High Throughput Sequencing (in vitro)
- Genetic: Patient Derived Xenograft (PDX)(in vivo)
- Other: Liquid Biopsy
- label
- Rare tumors
- description
- At least one of the following three criteria must be met: 1. A rare tumor of uncertain prognosis due to rarity of disease 2. A rare tumor with no established treatment strategy 3. A cancer where routine histopathological examination has not been able to establish a diagnosis 4. Confirmed histiocytic disorder AND molecular profiling may facilitate diagnosis and/or treatment 5. Confirmed proliferative vascular or lymphatic malformation AND has failed conventional treatment, e.g., surgery or embolization, OR no appropriate treatment is available AND the disease is organ, limb or life threatening, or debilitating
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age \< 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate. 2. Life expectancy \>6 weeks at time of enrolment 3. Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged \<18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.
References
Publications (0)
Data not yet available
No reference posted for this study.